Advertisement

Journal of Gastrointestinal Cancer

, Volume 48, Issue 3, pp 274–275 | Cite as

Hepatocellular Cancer: Is Recurrence Inevitable?

  • Levent DoganayEmail author
Review Article
  • 60 Downloads

Introduction

Hepatocellular cancer (HCC) ranks as the sixth common cancer in the world [1]. Yearly, it is estimated that more than 700,000 people are diagnosed with HCC. However, when it comes to mortality, it is the second cause [1, 2]. More than half of the HCC patients are from East Asia and the most prevalent liver disease causing HCC is chronic hepatitis B (HBV) infection there. The other underlying disorders are chronic hepatitis C infection, alcohol abuse, and metabolic syndrome. Tobacco smoking and dietary aflatoxin exposure are additional confounding factors [3].

Despite advances in medicine, recurrence after HCC treatment are unacceptably high. In the long-term recurrence, free survival is less than 40% after loco-regional treatments [4]. Here, the current literature in recurrence of HCC is reviewed.

Curative Strategies in HCC Treatment and Recurrence

HCC treatment algorithm is not built on a TNM staging system. Barcelona Clinic Liver Cancer (BCLC) staging system in wide use,...

References

  1. 1.
    Forman D, Ferlay J. The global and regional burden of cancer. In: Stewart BW, Wild CP, editors. World cancer report. Lyon: IARCPress; 2014. p. 16–53.Google Scholar
  2. 2.
    Mortality GBD. Causes of Death C. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1459–544.CrossRefGoogle Scholar
  3. 3.
    Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018.CrossRefGoogle Scholar
  4. 4.
    Wang Y, Luo Q, Li Y, Deng S, Wei S, Li X. Radiofrequency ablation versus hepatic resection for small hepatocellular carcinomas: a meta-analysis of randomized and nonrandomized controlled trials. PLoS One. 2014;9(1):e84484.CrossRefGoogle Scholar
  5. 5.
    Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379(9822):1245–55.CrossRefGoogle Scholar
  6. 6.
    Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology. 2008;47(1):82–9.CrossRefGoogle Scholar
  7. 7.
    Taefi A, Abrishami A, Nasseri-Moghaddam S, Eghtesad B, Sherman M. Surgical resection versus liver transplant for patients with hepatocellular carcinoma. Cochrane Database Syst rev. 2013;6:CD006935.Google Scholar
  8. 8.
    Rahman A, Assifi MM, Pedroso FE, Maley WR, Sola JE, Lavu H, et al. Is resection equivalent to transplantation for early cirrhotic patients with hepatocellular carcinoma? A Meta-Analysis J Gastrointest Surg. 2012;16(10):1897–909.CrossRefGoogle Scholar
  9. 9.
    Marubashi S, Gotoh K, Akita H, Takahashi H, Ito Y, Yano M, et al. Anatomical versus non-anatomical resection for hepatocellular carcinoma. Br J Surg. 2015;102(7):776–84.CrossRefGoogle Scholar
  10. 10.
    Sasaki K, Shindoh J, Margonis GA, Nishioka Y, Andreatos N, Sekine A, et al. Effect of background liver cirrhosis on outcomes of hepatectomy for hepatocellular carcinoma. JAMA Surg. 2017:e165059.CrossRefGoogle Scholar
  11. 11.
    Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16(13):1344–54.CrossRefGoogle Scholar
  12. 12.
    Toso C, Asthana S, Bigam DL, Shapiro AM, Kneteman NM. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the scientific registry of transplant recipients database. Hepatology. 2009;49(3):832–8.CrossRefGoogle Scholar
  13. 13.
    Mazzaferro V, Bhoori S, Sposito C, Bongini M, Langer M, Miceli R, et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl. 2011;17(Suppl 2):S44–57.CrossRefGoogle Scholar
  14. 14.
    Wu CY, Chen YJ, Ho HJ, Hsu YC, Kuo KN, Wu MS, et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA. 2012;308(18):1906–14.CrossRefGoogle Scholar
  15. 15.
    van der Meer AJ, Wedemeyer H, Feld JJ, Dufour JF, Zeuzem S, Hansen BE, et al. Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population. JAMA. 2014;312(18):1927–8.CrossRefGoogle Scholar
  16. 16.
    Zavaglia C, Okolicsanyi S, Cesarini L, Mazzarelli C, Pontecorvi V, Ciaccio A, et al. Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured? J Hepatol. 2017;66(1):236–7.CrossRefGoogle Scholar
  17. 17.
    Chan KM, Kuo CF, Hsu JT, Chiou MJ, Wang YC, Wu TH, et al. Metformin confers risk reduction for developing hepatocellular carcinoma recurrence after liver resection. Liver Int. 2017;37(3):434–41.CrossRefGoogle Scholar
  18. 18.
    Geissler EK, Schnitzbauer AA, Zulke C, Lamby PE, Proneth A, Duvoux C, et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial. Transplantation. 2016;100(1):116–25.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.Department of Gastroenterology and HepatologyUmraniye Teaching and Research HospitalIstanbulTurkey
  2. 2.Gastroenteroloji KlinigiUmraniye Egitim ve Arastirma HastanesiIstanbulTurkey

Personalised recommendations